This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Hikma Pharmaceuticals (HIK) - Given the all clear by US FDA relating to Portugal facility, allowing acceleration of introduction of new products to market. Closing price 1953.00p (Reuters)
Barclays (BARC) - Will pay at least another $100m in a settlement with the New York financial regulator to resolve allegations that it rigged foreign exchange markets. Closing price 227.45p (Reuters)
Royal Bank of Scotland (RBS) - Federal prosecutors pursuing criminal cases against RBS and JPMorgan Chase execs for allegedly selling flawed mortgage securities, the Wall Street Journal reported. Closing price 311.00p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Easyjet | EZJ | -4.09% | -1.63% | -5.55% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research